Findings showed that the 2-drug regimen (2DR) of dolutegravir plus lamivudine continued to offer non-inferior efficacy... Oct 05
Dr. Reddy’s Laboratories Ltd. has joined the SBTi becoming the first Indian and the third Asian pharma company to further minimize environmental impact... Oct 05
-Advertisements-